INTERCEPT PHARMACEUTICALS, INC.

NEW YORK, NY How do I update this listing?

Intercept Pharmaceuticals is based out of New York. Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea.Whalewisdom has at least 1 13G filings, and 365 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2012-09-04. The notice included securities offered of Equity

Create Alert

Contact Info

intercept pharmaceuticals, inc.
10 HUDSON YARDS, 37TH FLOOR
NEW YORK NY    10001

Business Phone: 646-747-1000
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2012-09-04 D/A BIOTECHNOLOGY Equity 50,000,000 30,000,000 20,000,000
2012-08-24 D BIOTECHNOLOGY Equity 30,000,000 15,000,000 15,000,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
BARBARA DUNCAN subscription required
    EXECUTIVE OFFICER
DAVID SHAPIRO subscription required
    EXECUTIVE OFFICER
JONATHAN T. SILVERSTEIN subscription required
    DIRECTOR
KLAUS VEITINGER subscription required
    DIRECTOR
KLAUS VELTINGER subscription required
    DIRECTOR
LORENZO TALLARIGO subscription required
    DIRECTOR
LUCIANO ADORINI subscription required
    EXECUTIVE OFFICER
MARK E. PRUZANSKI subscription required
    EXECUTIVE OFFICER DIRECTOR
NICOLE WILLIAMS subscription required
    DIRECTOR
PAOLO FUNDARO subscription required
    DIRECTOR

Elevate your investments